Evidence map›Paper›PMID 39630611›Full record

ArticleMolecular biology of the cell2025

Breast cancer cells promote osteoclast differentiation in an MRTF-dependent paracrine manner.

Pooja Chawla, Ishani Sharma, David Gau, Ian Eder, Fangyuan Chen, Virginia Yu, Niharika Welling, David Boone, Juan Taboas, Adrian V Lee and 3 more

Abstract read
In one paragraph

Article in Molecular biology of the cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Pooja ChawlaBioengineering, University of Pittsburgh, Pittsburgh, PA 15219.
Ishani SharmaBioengineering, University of Pittsburgh, Pittsburgh, PA 15219.
David GauBioengineering, University of Pittsburgh, Pittsburgh, PA 15219.
Ian EderBioengineering, University of Pittsburgh, Pittsburgh, PA 15219.
Fangyuan ChenSchool of Medicine, University of Pittsburgh, Pittsburgh, PA 15261.
Virginia YuBioengineering, University of Pittsburgh, Pittsburgh, PA 15219.
Niharika WellingComputational and Systems Biology, University of Pittsburgh, Pittsburgh, PA 15213.
David BooneBiomedical Informatics, University of Pittsburgh, Pittsburgh, PA 15206.
Juan TaboasBioengineering, University of Pittsburgh, Pittsburgh, PA 15219.
Adrian V LeePharmacology, University of Pittsburgh, Pittsburgh, PA 15213.
Adriana LarreginaDermatology, University of Pittsburgh, Pittsburgh, PA 15213.
Deborah L GalsonHematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15261.
Partha RoyBioengineering, University of Pittsburgh, Pittsburgh, PA 15219.ORCID 0000-0002-4946-8531

Funding

NRSA Training CoreTL1TR001858 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RADOMSKI, THOMAS, RUBIO, DORIS M · 2016 to 2025
$11.1M
Cellular Approaches to Tissue Engineering/RegenerationT32EB001026 · NIBIB · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DUNCAN, ANDREW W, MONGA, SATDARSHAN SINGH · 2003 to 2024
$5.5M
Training Program in Imaging Sciences in Translational Cardiovascular ResearchT32HL129964 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Flordeliza S Villanueva · 2016 to 2026
$4.7M
Profilin biology in breast cancerR01CA248873 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ROY, PARTHA · 2021 to 2025
$1.8M
Transcriptional Regulation of Dormancy and Emergence in Breast CancerR01CA271095 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PARTHA ROY · 2023 to 2026
$1.5M
Profilin as a Novel Target for Vascular Normalization in Renal CancerR00CA267180 · NCI · UNIVERSITY OF TEXAS DALLAS · PI David Martin Gau · 2024 to 2026
$747k
Discovery of Cell-based Chemical Probes Targeting Aberrant Angiogenesis in the EyeR21EY032632 · NEI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HURYN, DONNA M, KOES, DAVID RYAN · 2022 to 2023
$426k
Profilin as a Novel Target for Vascular Normalization in Renal CancerK99CA267180 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GAU, DAVID MARTIN · 2022 to 2023
$252k
NCATS NIH HHS TL1 TR001858NCI NIH HHS K99 CA267180NCI NIH HHS R00 CA267180NCI NIH HHS R01 CA248873NCI NIH HHS R01 CA271095NEI NIH HHS R21 EY032632NHLBI NIH HHS T32 HL129964NIBIB NIH HHS T32 EB001026
6 · The paper itself

Abstract

Bone is a frequent site for breast cancer metastasis. The vast majority of breast cancer-associated metastasis is osteolytic in nature, and RANKL (receptor activator for nuclear factor κB)-induced differentiation of bone marrow-derived macrophages to osteoclasts (OCLs) is a key requirement for osteolytic metastatic growth of cancer cells. In this study, we demonstrate that Myocardin-related transcription factor (MRTF) in breast cancer cells plays an important role in paracrine modulation of RANKL-induced OCL differentiation. This is partly attributed to MRTFs' critical role in maintaining the basal cellular expression of connective tissue growth factor (CTGF), findings that align with a strong positive correlation between CTGF expression and MRTF-A gene signature in the human disease context. Luminex analyses reveal that MRTF depletion in breast cancer cells has a broad impact on OCL-regulatory cell-secreted factors that extend beyond CTGF. Experimental metastasis studies demonstrate that MRTF depletion diminishes OCL abundance and bone colonization of breast cancer cells in vivo, suggesting that MRTF inhibition could be an effective strategy to diminish OCL formation and skeletal involvement in breast cancer. In summary, this study highlights a novel tumor-extrinsic function of MRTF relevant to breast cancer metastasis.

Indexed as

Breast NeoplasmsCell DifferentiationConnective Tissue Growth FactorOsteoclastsParacrine CommunicationRANK LigandTrans-ActivatorsAnimalsBone NeoplasmsCell Line, TumorFemaleHumansMacrophagesMiceCCN2 protein, humanConnective Tissue Growth FactorMRTFA protein, humanRANK LigandTrans-Activators

Identifiers

PMID39630611
PMCPMC11742114

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.